Aruvant is a clinical-stage biotech focused on developing and commercializing gene therapies for hematological and other diseases. As part of the Roivant family of companies, we aim to systematically reduce the time, cost, and risk of delivering new medicines to market by accelerating the development of promising drug candidates to improve the lives of patients and their families. The company has a talented team with extensive experience in the development, manufacturing, and commercialization of gene therapy products. The company is privately held and very well-capitalized.

Aruvant’s lead asset is ARU-1801, an ex-vivo lentiviral gene therapy currently under investigation for the treatment of sickle cell anemia utilizing reduced-intensity conditioning. Unlike other investigational gene therapies for SCD, ARU-1801 is the only gene therapy that can be successfully administered with lower doses of chemotherapy, which could result in a lower risk of bleeding and infection and lower resource utilization than other gene therapies. ARU-1801 is currently in clinical trials, and results from the first treated patients have demonstrated durable efficacy and a differentiated toxicity profile.

The company’s second candidate, ARU-2801, is a preclinical adeno-associated virus (“AAV”) gene therapy designed to deliver potentially curative efficacy without chronic administration for patients with hypophosphatasia (“HPP”). This devastating, ultra-orphan disorder can result in multi-organ damage and high mortality when left untreated. HPP is caused by mutations in the gene encoding the tissue non-specific alkaline phosphatase (“TNS-ALP”) enzyme and is remarkably wide-ranging in severity. Preclinical research shows that treatment of HPP disease model mice with ARU-2801 results in sustained elevation of TNAP at levels that ameliorated disease symptoms and extended survival. For more information, please visit www.aruvant.com.

**Position Title: Summer 2022 Intern, Graduate Student, Competitive Intelligence**

The company has a talented team with extensive experience in the development, manufacturing, and commercialization of gene therapy products. We are committed to developing the next generation of leaders in the biotech and pharmaceutical industry by providing opportunities for students. This internship opportunity will offer motivated students the opportunity to apply their skills and grow professionally and personally. Students will learn and work alongside research and business professionals who will provide mentorship and guidance.

**Responsibilities:**

- Help build and maintain an up-to-date view of the competitive landscape for sickle cell disease and hypophosphatasia. Use to provide context and insight into strategic decision-making and key messaging, as well as support business development objectives.
  - Staying on top of news flow from multiple sources
  - Organizing data, insights, and questions
  - Building views on companies, programs, and data, placed in broader context
  - Performing analyses as-needed
  - Identifying and profiling strategic business partners
  - Being a knowledge resource for others in the company

**Qualifications and Skills:**

- Graduate student, scientific major (eg. life science, physical science, engineering, etc.)
- Attention to detail and strong organizational skills
- Curiosity and drive to go above and beyond in service of a goal
- Proficiency with Excel and PowerPoint

**Working Environment:**

- Dynamic, interactive, fast-paced, and entrepreneurial environment
- Collegiate and collaborative culture
- Committed team with a passion for asset and compassion for patients

**Diversity, Inclusion, and Equality**

We are each different and are better because of it. We are proud of the diverse and inclusive organization we have built. We support the Biotechnology Innovation Organization (BIO) principles on workforce development, diversity, and inclusion (WDDI) and pledge to do our part to foster diversity and inclusion among our employees, customers, and patients. No agencies, please. Unsolicited resumes will become the sole property of Aruvant Sciences, Inc.